OverviewSuggest Edit

Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings in 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

TypePublic
Founded2006
HQOxford, GB
Websitecircassia.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Sept 2020)350
Job Openings2
Revenue (FY, 2016)£17 K
Share Price (Oct 2020)£0.3 (-1%)
Cybersecurity ratingAMore

Key People/Management at Circassia

Ian Johnson

Ian Johnson

Executive Chairman
Jonathan Emms

Jonathan Emms

Chief Operating Officer, Director
Jo le Couilliard

Jo le Couilliard

Non-Executive Director
Garry Watts

Garry Watts

Senior Independent Director
Sharon Curran

Sharon Curran

Non-Executive Director
Darren Mercer

Darren Mercer

Regional Vice President EMEA
Show more

Circassia Office Locations

Circassia has offices in Oxford, London, Morrisville, Bad Homburg vor der Höhe and in 1 other location
Oxford, GB (HQ)
The Oxford Science Park
London, GB
10 Paternoster Sq.
Bad Homburg vor der Höhe, DE
Louisenstraße 21
Uppsala, SE
Hansellisgatan
Morrisville, US
5151 McCrimmon Pkwy
Show all (6)

Circassia Financials and Metrics

Circassia Revenue

Circassia's revenue was reported to be £17 k in FY, 2016
GBP

Revenue (FY, 2016)

17.0k

Net income (FY, 2016)

17.0k

EBITDA (FY, 2016)

17.0k

EBIT (FY, 2016)

17.0k

Market capitalization (19-Oct-2020)

100.0m

Closing stock price (19-Oct-2020)

0.3
Circassia's current market capitalization is £100 m.
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

17.0k

EBITDA

(624.7k)(362.3k)(188.0k)(3.0k)17.0k

EBITDA margin, %

100%

EBIT

(624.7k)(362.3k)(295.0k)(3.0k)17.0k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Accounts Receivable

1.017.2k104.4k27.0k1.0k

Current Assets

19.6k1.01.017.2k104.4k27.0k1.0k

Total Assets

19.6k1.0106.8k124.0k211.2k27.0k1.0k

Accounts Payable

190.5k34.6k84.7k154.3k21.0k2.3m2.3m
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(624.7k)(362.3k)(269.0k)(2.0k)(1.0k)17.0k

Income Taxes Paid

26.0k1.0k(1.0k)
Show all financial metrics

Circassia Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Circassia Online and Social Media Presence

Embed Graph

Circassia News and Updates

Remembering when European migrants once flocked to North African shores

“Praise be to God. To my master, may god preserve you. After our master scolded me and became angry with me, accusing me of having…

Allergy Treatment Global Market 2018: Key Players – ALK, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Circassia

Allergy Treatment -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

World Allergy Immunotherapy Market is Estimated to Reach USD 4,324.7 million by 2023

Market Research Future published a cooked research report on “Global Allergy Immunotherapy Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday

Circassia Blogs

Circassia Announces Duaklir® US Launch at American College of Chest Physicians’ CHEST Annual Meeting 2019

Click here to download the full press release – Duaklir® launch expands Circassia’s US portfolio of COPD products alongside Tudorza® – Oxford, UK and Morrisville, NC, United States – 21 October 2019: Circassia Pharmaceuticals plc...

Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer

Click here to download the full press release – COO to join Board and SVP R&D to step down as Director reflecting Company’s commercial focus – Oxford, UK – 12 August 2019: Circassia Pharmaceuticals plc...

Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association

Click here to download full press release Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication...

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Click here to download the full press release – Duaklir® launch planned H2 2019 – – Duaklir® to join Tudorza® in Circassia’s portfolio of US COPD products – Oxford, UK – 1 April 2019: Circassia...

Circassia Announces FDA Approval of Tudorza® Supplemental New Drug Application

This announcement contains inside information for purposes of Article 7 of Market Abuse Regulation 596/2014 Click here to download the full press release – Data showing reduction in COPD exacerbations and no increase in major...

Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent

Click here to download the full press release Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its partner,...
Show more

Circassia Frequently Asked Questions

  • When was Circassia founded?

    Circassia was founded in 2006.

  • Who are Circassia key executives?

    Circassia's key executives are Ian Johnson, Jonathan Emms and Jo le Couilliard.

  • How many employees does Circassia have?

    Circassia has 350 employees.

  • What is Circassia revenue?

    Latest Circassia annual revenue is £17 k.

  • What is Circassia revenue per employee?

    Latest Circassia revenue per employee is £49 .

  • Who are Circassia competitors?

    Competitors of Circassia include Durect, BTG and Zogenix.

  • Where is Circassia headquarters?

    Circassia headquarters is located at The Oxford Science Park, Oxford.

  • Where are Circassia offices?

    Circassia has offices in Oxford, London, Morrisville, Bad Homburg vor der Höhe and in 1 other location.

  • How many offices does Circassia have?

    Circassia has 6 offices.